Magenta Therapeutics, Inc. — Q2 2019 Form 10-Q
Issuer identity: The supplied filing is for Magenta Therapeutics, Inc. (Nasdaq: MGTA), not Dianthus Therapeutics, Inc. It covers the quarter and six months ended June 30, 2019; filed August 8, 2019. Financial amounts below are in U.S. dollars.
Business context and reporting period
Magenta was a clinical-stage biotechnology company developing therapies to improve stem-cell transplant and related procedures. It had no approved products and no product revenue. Its programs included MGTA-456 (stem-cell expansion), MGTA-145 (mobilization), conditioning therapies, and graft-versus-host disease research. In April 2019, the company dosed the first subjects in a Phase 1 MGTA-145 trial. MGTA-456 was being studied in Phase 2 trials for inherited metabolic disorders and blood cancers.
Financial performance, liquidity and debt
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 | Prior-year comparison |
|---|---|---|---|
| Revenue | $0 | $0 | $0 in both 2018 periods |
| Research and development expense | $13.4 million | $24.0 million | Up 39% and 37%, respectively |
| General and administrative expense | $5.9 million | $11.7 million | Up 36% and 50%, respectively |
| Total operating expenses | $19.3 million | $35.7 million | Up 38% and 41%, respectively |
| Net loss | $17.7 million | $32.5 million | Compared with $13.7 million and $24.8 million |
| Net loss per share, basic and diluted | $0.48 | $0.93 | Compared with $3.13 and $7.25; weighted-average share counts differed substantially |
| Cash used in operating activities | Not separately stated | $30.0 million | $18.7 million used in first half 2018 |
At June 30, 2019, cash and cash equivalents were $33.1 million and marketable securities were $139.2 million, totaling $172.3 million in cash, cash equivalents and marketable securities. Total assets were $195.4 million; total liabilities were $15.9 million, including $9.9 million of current liabilities. The filing reports no debt balance. The company stated that its resources were expected to fund operations and capital expenditures into the second half of 2021, while cautioning that estimates could prove wrong and additional capital would eventually be needed.
First-half investing cash outflow was $56.6 million, primarily reflecting net purchases of marketable securities and $2.4 million of property and equipment. Financing provided $61.3 million, principally from the May follow-on offering. The company sold 4,887,500 shares at $13.25 per share, receiving net proceeds of approximately $60.3 million. No operating profit or meaningful operating margin was reported; the company remained loss-making.
Material changes, outlook and risks
- Compared with first-half 2018, the net loss increased by $7.7 million as operating expenses rose by $10.4 million. Higher research costs reflected clinical-trial and manufacturing activity, including MGTA-145 trial start-up and MGTA-456 development; higher facility and public-company costs also contributed.
- Interest and other income rose to $3.1 million for the first half, from $0.5 million, partly due to investment income and rental income from subleasing Cambridge space.
- The Cambridge sublease was amended in March 2019, increasing payments by $6.1 million over the term and adding $4.9 million of landlord-funded tenant improvements. Future minimum lease payments were reported as $59.8 million. The lease runs to February 2028, subject to the sublandlord’s termination right after five years.
- Management expected expenses and operating losses to increase as research and clinical programs advanced. No specific financial guidance beyond the stated cash runway was provided.
- Key risks included clinical-trial failure or delay, patient enrollment and safety, manufacturing and contamination issues, dependence on third parties and licensed intellectual property, competition, regulatory approval, reimbursement, and the need for future financing. The filing notes limited serious adverse events considered related to MGTA-456 in the blood-cancer Phase 2 trial; it also describes a patient death following autoimmune cytopenia in the MGTA-456 study, which the company said was deemed unrelated to MGTA-456.
- Potential future license obligations include up to $177.0 million in clinical and regulatory milestones and up to $125.0 million in commercial milestones under the Novartis license, plus royalties; no Novartis milestones had been met by June 30, 2019. Other agreements also include potential milestone payments and royalties. These are contingent obligations, not current recorded debt.
- Management said disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter. The company reported no material legal proceedings.
Important facts for investors to verify
- Confirm issuer identity: this is Magenta Therapeutics, not Dianthus Therapeutics.
- Review subsequent clinical and safety updates for MGTA-456 and MGTA-145, including trial enrollment, outcomes, and adverse events.
- Assess cash use against the stated runway into the second half of 2021 and the company’s expectation that further funding would be required.
- Check the terms, timing, and potential financial impact of the sublease, tenant-improvement funding, and contingent licensing milestones and royalties.
- When comparing loss per share year over year, account for the substantial change in weighted-average shares following the 2018 IPO and subsequent equity financing.